CBMX Combimatrix Corp. (MM)

CombiMatrix Corporation (Nasdaq:CBMX) announced today that Mark McDonough, President and Chief Executive Officer of CombiMatrix, will present at the 27th Annual ROTH Conference at 10:30 a.m. PDT on March 11, at The Ritz Carlton in Laguna Niguel, Calif.

A live webcast of the presentation will be available on the CombiMatrix website at www.combimatrix.com. The presentation will be archived on the Company's website and available for viewing 90 days following the event.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic screening (PGS), prenatal diagnosis, miscarriage analysis, and pediatric genetics, offering DNA‑based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization ("FISH") and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
         
         Media Contact:
         David Schull or Lena Evans
         Russo Partners LLC
         (212) 845-4271 or (212) 845-4262
         david.schull@russopartnersllc.com
         lena.evans@russopartnersllc.com

         Investor Contact:
         Robert Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         robert.flamm@russopartnersllc.com